KROS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KROS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Keros Therapeutics's Enterprise Value is $1,797.59 Mil. Keros Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-152.99 Mil. Therefore, Keros Therapeutics's EV-to-EBIT ratio for today is -11.75.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Keros Therapeutics's Enterprise Value is $1,797.59 Mil. Keros Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-152.18 Mil. Therefore, Keros Therapeutics's EV-to-EBITDA ratio for today is -11.81.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Keros Therapeutics's Enterprise Value is $1,797.59 Mil. Keros Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.15 Mil. Therefore, Keros Therapeutics's EV-to-Revenue ratio for today is 11,904.58.
The historical data trend for Keros Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Enterprise Value | Get a 7-Day Free Trial | - | 1,371.05 | 1,173.82 | 1,056.85 | 949.30 |
Keros Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | 1,056.85 | 924.29 | 883.70 | 672.59 | 949.30 |
For the Biotechnology subindustry, Keros Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Keros Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1266.002136 | + | 0 | + | 13.439 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 1.005 | + | 0 | - | 331.147 |
= | 949.30 |
Keros Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1266.002136 | + | 0 | + | 13.439 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 1.005 | + | 0 | - | 331.147 |
= | 949.30 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (NAS:KROS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Keros Therapeutics's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 1797.591 | / | -152.992 | |
= | -11.75 |
Keros Therapeutics's current Enterprise Value is $1,797.59 Mil.
Keros Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-152.99 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Keros Therapeutics's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 1797.591 | / | -152.177 | |
= | -11.81 |
Keros Therapeutics's current Enterprise Value is $1,797.59 Mil.
Keros Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-152.18 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Keros Therapeutics's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 1797.591 | / | 0.151 | |
= | 11,904.58 |
Keros Therapeutics's current Enterprise Value is $1,797.59 Mil.
Keros Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Keros Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith Regnante | officer: Chief Financial Officer | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Jennifer Lachey | officer: Chief Scientific Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Christopher Rovaldi | officer: Chief Operating Officer | C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139 |
Julius Knowles | director | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Simon Peter Cooper | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421 |
Claudia Ordonez | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Pontifax Management 4 G.p. (2015) Ltd. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Tomer Kariv | director, 10 percent owner | C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Ran Nussbaum | director, 10 percent owner | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jasbir Seehra | director, officer: Chief Executive Officer | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451 |
Arkin Bio Ventures Limited Partnership | 10 percent owner | 6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406 |
From GuruFocus
By sperokesalga sperokesalga • 05-22-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By Marketwired • 07-27-2023
By Value_Insider Value_Insider • 11-03-2022
By sperokesalga sperokesalga • 06-07-2023
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 07-03-2022
By sperokesalga sperokesalga • 06-12-2023
By Value_Insider Value_Insider • 12-12-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.